<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513058</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000558406</org_study_id>
    <secondary_id>FRE-FNCLCC-GEP-01/0506</secondary_id>
    <secondary_id>2005-005167-28</secondary_id>
    <nct_id>NCT00513058</nct_id>
  </id_info>
  <brief_title>Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>Phase I Study Evaluating the Combination of Lapatinib + Vinorelbine in Patients With Locally Advanced or Metastatic Breast Cancer Overexpressing HER2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving lapatinib together with vinorelbine may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib and&#xD;
      vinorelbine in treating women with HER2-overexpressing locally advanced or metastatic breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the tolerability and feasibility of the lapatinib ditosylate and vinorelbine&#xD;
           ditartrate combination by determining the maximum tolerated dose of vinorelbine&#xD;
           ditartrate in combination with a biologically active dose of lapatinib ditosylate.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the maximum administered dose.&#xD;
&#xD;
        -  Investigate the pharmacokinetic interactions related to the combination of vinorelbine&#xD;
           ditartrate and lapatinib ditosylate.&#xD;
&#xD;
        -  Determine the toxicity of vinorelbine ditartrate and lapatinib ditosylate.&#xD;
&#xD;
        -  Determine the objective response rate in patients with measurable lesions.&#xD;
&#xD;
        -  Validate the safety and efficacy of the oral vinorelbine ditartrate and lapatinib&#xD;
           ditosylate combination, according to the vinorelbine ditartrate oral/IV dose&#xD;
           equivalence.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study.&#xD;
&#xD;
      Patients receive oral lapatinib ditosylate on days -7 to 21 for course 1 and on days 1-21 for&#xD;
      all other courses. Patients also receive vinorelbine ditartrate IV over 15 minutes on days 1&#xD;
      and 8. Courses repeat every 21 days for up to 12 months in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-9 patients receive escalating doses of lapatinib ditosylate and vinorelbine&#xD;
      ditartrate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the&#xD;
      dose preceding that at which 2 of 9 patients experience dose-limiting toxicity during course&#xD;
      1.&#xD;
&#xD;
      Once the MTD is determined for oral lapatinib ditosylate and IV vinorelbine ditartrate, an&#xD;
      additional cohort of 9 patients receive oral vinorelbine ditartrate with oral lapatinib&#xD;
      ditosylate as above.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity as assessed by NCI CTCAE v3.0</measure>
    <time_frame>during the first cycle of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic interactions between vinorelbine ditartrate (oral or IV) and lapatinib ditosylate</measure>
    <time_frame>during the first cycle of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response as assessed by RECIST criteria after every 2 courses</measure>
    <time_frame>during 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>lapatinib + vinorelbine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>starting with loading dose of lapatinib per os for 7 days&#xD;
then, combining lapatinib (oral daily continuous) + vinorelbine (intravenous, day 1 and 8 every 3 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>Dose level (DL) 1 : 750 mg/d DL2, DL3, DL4: 1000 mg/d DL5, DL7, DL8: 1250 mg/d DL6: 1500 mg/d</description>
    <arm_group_label>lapatinib + vinorelbine</arm_group_label>
    <other_name>TYVERB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
    <description>DL1, DL2: 20 mg/m2 DL3: 22.5 mg/m2 DL4, DL5, DL6: 25 mg/m2 DL7: 27.5 mg/m2 DL8: 30 mg/m2</description>
    <arm_group_label>lapatinib + vinorelbine</arm_group_label>
    <other_name>NAVELBINE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced breast cancer (metastatic or locally advanced)&#xD;
&#xD;
          -  Tumor overexpressing HER2 (HER2 3+ by IHC OR HER2 2+ by IHC and FISH positive) in&#xD;
             samples from the primary and/or secondary tumor&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Cancer is progressive after treatment with at least 1 line or, at most, 2 lines, of&#xD;
             chemotherapy that included trastuzumab (Herceptin®)&#xD;
&#xD;
          -  Patients presenting with treated asymptomatic cerebral metastases or leptomeningeal&#xD;
             metastases may be included if they are neurologically stable and have not received&#xD;
             steroids or anticonvulsant treatment for at least 4 weeks before study entry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Patients must have an estimated survival of at least 3 months&#xD;
&#xD;
          -  WHO performance status (ECOG) 0-2&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelets ≥ 100,000/mm³&#xD;
&#xD;
          -  Total bilirubin ≤ 2.5 mg/dL&#xD;
&#xD;
          -  ALT and AST ≤ 3 times upper limit of normal&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  LVEF ≥ 50% (echographic or isotopic method)&#xD;
&#xD;
          -  Potentially reproductive patients must agree to use an effective contraceptive method&#xD;
             while on study treatment&#xD;
&#xD;
          -  Patients must be affiliated with a Social Security system&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Uncontrolled cardiac pathology&#xD;
&#xD;
          -  Dysphagia or inability to swallow the vinorelbine ditartrate soft capsules&#xD;
&#xD;
          -  Malabsorption syndrome or disease significantly affecting gastrointestinal function&#xD;
&#xD;
          -  Preexisting neuropathy (grade ≥ 2)&#xD;
&#xD;
          -  Pregnant women, women who are likely to become pregnant, or women who are&#xD;
             breastfeeding&#xD;
&#xD;
          -  Any psychological, familial, sociological, or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  Individuals deprived of liberty&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior major resection of stomach or proximal bowel that could affect absorption of&#xD;
             oral drugs&#xD;
&#xD;
          -  Prior vinorelbine&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Fumoleau, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Georges Francois Leclerc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92211</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <last_update_submitted>January 13, 2014</last_update_submitted>
  <last_update_submitted_qc>January 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic breast cancer</keyword>
  <keyword>advanced breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

